Cibus (NASDAQ:CBUS) Releases Earnings Results, Misses Expectations By $0.16 EPS

Cibus (NASDAQ:CBUS) issued its quarterly earnings data on Tuesday. The company reported ($0.59) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.43) by ($0.16), FiscalAI reports. Cibus had a negative net margin of 3,133.92% and a negative return on equity of 133.90%. The company had revenue of $1.06 million during the quarter, compared to analysts’ expectations of $1.64 million.

Cibus Trading Up 3.4%

NASDAQ:CBUS traded up $0.12 during midday trading on Tuesday, reaching $3.68. The company had a trading volume of 437,343 shares, compared to its average volume of 474,489. Cibus has a 12-month low of $1.09 and a 12-month high of $4.19. The firm has a market capitalization of $199.75 million, a price-to-earnings ratio of -1.13 and a beta of 1.62. The stock’s fifty day simple moving average is $2.59 and its 200-day simple moving average is $1.86.

Wall Street Analyst Weigh In

CBUS has been the subject of a number of recent analyst reports. Weiss Ratings reiterated a “sell (e+)” rating on shares of Cibus in a research report on Wednesday, January 21st. Canaccord Genuity Group reaffirmed a “buy” rating and set a $15.00 price objective on shares of Cibus in a research report on Monday, December 8th. Two analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, Cibus currently has an average rating of “Hold” and an average price target of $20.00.

Hedge Funds Weigh In On Cibus

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. PACK Private Wealth LLC purchased a new position in shares of Cibus during the fourth quarter worth about $27,000. Qube Research & Technologies Ltd acquired a new stake in shares of Cibus during the second quarter worth about $39,000. Bank of America Corp DE lifted its holdings in shares of Cibus by 113.4% in the 4th quarter. Bank of America Corp DE now owns 35,536 shares of the company’s stock valued at $99,000 after purchasing an additional 18,885 shares during the last quarter. AQR Capital Management LLC acquired a new stake in shares of Cibus in the 1st quarter valued at about $73,000. Finally, Squarepoint Ops LLC acquired a new stake in shares of Cibus in the 3rd quarter valued at about $62,000. 33.81% of the stock is owned by institutional investors and hedge funds.

About Cibus

Cibus, Inc is a biotechnology company specializing in precision gene editing for agricultural applications. Leveraging its proprietary Rapid Trait Development System (RTDS), Cibus develops improved crop traits without the introduction of foreign DNA. The company’s platform enables targeted modifications to plant genomes, allowing for enhanced disease resistance, herbicide tolerance and yield optimization in key row crops.

The company’s core business centers on trait development services and licensing partnerships.